MINT

Phase 2

• Conditions: eoplasms, Breast Neoplasms, Breast Cancer

• Registration Number: JPRN-jRCT2080221559
• Lead Sponsor: AstraZeneca

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-09-02
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Patients that have locally advanced or metastatic breast cancer. Lesions should not be amenable to surgery or radiation of curative intent

- Hormone therapy-naive

- Estimated life expectancy of more than 12 weeks

Exclusion Criteria

- Last dose of prior anti-cancer therapy received within 14 days (or longer if required)

- Any eye injury or corneal surgery within 3 months prior to receiving first dose of study drug.

- Currently receiving (and unwilling to discontinue) oestrogen replacement therapy. (last dose <7 days prior to randomisation)

Study & Design

• Study Type: Interventional
• Study Design: Not specified